NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 218 filers reported holding NEVRO CORP in Q3 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $472,000 | +3.7% | 3,947 | -13.2% | 0.13% | -43.1% |
| Q1 2020 | $455,000 | +175.8% | 4,547 | +224.8% | 0.23% | +625.0% |
| Q4 2019 | $165,000 | +768.4% | 1,400 | +366.7% | 0.03% | +540.0% |
| Q2 2019 | $19,000 | +35.7% | 300 | -15.7% | 0.01% | 0.0% |
| Q4 2018 | $14,000 | -93.9% | 356 | -91.1% | 0.01% | -88.4% |
| Q3 2018 | $230,000 | +2455.6% | 4,000 | +3900.0% | 0.04% | +2050.0% |
| Q1 2018 | $9,000 | -67.9% | 100 | -75.0% | 0.00% | -66.7% |
| Q4 2017 | $28,000 | -74.3% | 400 | -66.7% | 0.01% | -75.0% |
| Q3 2017 | $109,000 | -79.5% | 1,200 | -83.2% | 0.02% | -69.2% |
| Q2 2017 | $532,000 | -43.2% | 7,145 | -28.6% | 0.08% | -27.8% |
| Q1 2017 | $937,000 | +92.4% | 10,000 | +49.2% | 0.11% | +77.0% |
| Q4 2016 | $487,000 | -8.5% | 6,701 | +31.4% | 0.06% | -11.6% |
| Q3 2016 | $532,000 | -18.9% | 5,100 | -42.7% | 0.07% | -24.2% |
| Q2 2016 | $656,000 | – | 8,900 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 562,833 | $40,710,000 | 4.84% |
| Altium Capital Management LP | 77,000 | $5,569,000 | 1.86% |
| PFM Health Sciences, LP | 649,513 | $46,979,000 | 1.76% |
| Rock Springs Capital Management LP | 721,500 | $52,186,000 | 1.31% |
| Integral Health Asset Management, LLC | 50,000 | $3,617,000 | 0.94% |
| Redmile Group, LLC | 411,017 | $29,729,000 | 0.93% |
| K2 PRINCIPAL FUND, L.P. | 114,800 | $8,303,000 | 0.72% |
| Connacht Asset Management LP | 18,762 | $1,357,000 | 0.70% |
| Perceptive Advisors | 477,037 | $34,504,000 | 0.69% |
| ArrowMark Colorado Holdings LLC | 855,439 | $61,874,000 | 0.54% |